159 results about "Thyreoidin" patented technology

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

Amino acid sequences of feline thyrotropin and polynucleotide sequences encoding feline thyrotropin are provided, as well as methods of making and using said sequences.

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and / or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

The invention belongs to the technical field of immunodiagnosis, and discloses a thyroxine (T4) enzymatic chemiluminescence quantitative determination kit. The kit disclosed by the invention consists of a T4 standard product, an antibody pre-coated reaction plate, a horseradish peroxidase marker, diluent, cleaning mixture, and chemiluminescence substrate liquid. The kit disclosed by the invention has the advantages of quickness, handiness, sensitiveness, cheapness and high repeatability, and is an important index for diagnosis and therapeutic evaluation of hyperthyroidism and hypothyroidism. The invention has high clinic use value. The invention also provides a method to prepare the kit.

The invention relates to a serum protein marker group for diagnosing MODY (maturity-onset-diabetes of the young) and application thereof. The serum protein marker group comprises five proteins: apolipoprotein C-IV (APOC4), apolipoprotein a (LPA), a complement component C6 (C6), a blood coagulation factor v (F5) and thyroid binding globulin (SERPINA7). ITRAQ (isobaric tags for relative and absolute quantitation) are used to combine with an MALDI-TOF / MS technology to detect; mass spectrum detection shows that expression levels of the serum apolipoprotein C-IV, the apolipoprotein a, the complement component C6 and the blood coagulation factor v protein in serum of a MODY patient are obviously improved, and an expression level of the thyroid binding globulin in the serum of the MODY patient is obviously reduced. Mass spectrum MRM (multiple-reaction-monitoring) also verifies that the five proteins are abnormal in expression in serums of the MODY patient, type-1 and type-2 diabetics and a healthy control group, and are specific proteins.

The present invention provides compositions comprising anti-transthyretin antibodies. The compositions are particularly useful for diagnosis, prognosis and / or treatment of amyloid diseases or symptoms thereof.

A compound of the formulawhere R1 is H, C1–C4 alkyl and OH; R2 in is H, C1–C4 alkyl and OH; R3 is H and C1–C4 alkyl; R4 is H and C1–C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2–C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

The present invention discloses a quantitative detection kit of free thyroxine (fT4) and a method for detecting the free thyroxine with the detection kit. The detection kit comprises a free thyroxine standard, a free thyroxine antigen marked by horseradish peroxidase, an antibody, a magnetic bead separating agent, luminescence substrate reagent and wash liquid. The method for detecting free thyroxine comprises the following steps: adding the free thyroxine standard and sample to be measured into the test tube, adding the free thyroxine antigen marked by horseradish peroxidase and antibody, after mixing to uniform, incubating for one hour in 37 DEG C, then adding magnetic bead separating agent for stewing for 5 minutes, separating for obtaining the immune magnetic microspheres, discarding the supernate, washing the deposit for two times; adding the luminescence substrate reagent, measuring and analyzing the concentration of free thyroxine in sample to be measured. The quantitative detection kit of free thyroxine and the detection method provided by the invention have the advantages of higher stability, higher sensitivity and higher accuracy, and belong to the technical field of immunodiagnosis.

The invention provides a method of diagnosing tuberculosis (TB) in a test subject, said method comprising: (i) providing expression data of two or more markers in a subject, wherein at least two of said markers are selected from transthyretin, neopterin, C-reactive protein (CRP), serum amyloid A (SAA), serum albumin, apoliopoprotein-A1 (Apo-A1), apolipoprotein-A2 (Apo-A2), hemoglobin beta, haptoglobin protein, DEP domain protein, leucine-rich alpha-2-glycoprotein (A2GL) and hypothetical protein DFKZp667I032; and (ii) comparing said expression data to expression data of said marker from a group of control subjects, wherein said control subjects comprise patients suffering from inflammatory conditions other than TB, thereby determining whether or not said test subject has TB.

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and / or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

The invention provides a thyrotropin (TSH) chemiluminescent immunoassay quantitative detection kit and a preparation method thereof. The invention has the advantages that the reaction pattern of the double antibody sandwich method is adopted, the chemiluminescent technology combining with the technology of fluorescin isothiocyanate-anti-fluorescein isothiocyanate is effectively utilized, horse radish peroxidase is adopted to be as the marker enzyme to quantitatively detect the content of TSH in the human serum sample, the detection sensitivity is guaranteed, and the raw materials are greatly saved. The kit of the invention has high sensitivity, good repeatability, short reaction time, good stability and long reagent validity, and can provide the experimental basis timely for the clinical diagnosis and the treatment of thyroid disorders.

Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and / or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and / or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent mild cognitive impairment (MCI) or Alzheimer's disease (AD), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, thyroxine (T4), triiodothyronine (T3) and combinations thereof.

The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

After reaction between bovine serum albumin (bsa) on magnetic particles and biotin label of thyroxin, superfluous biotin reagent in mixed liquor and n-hydroxyl succimide ester generates compound of magnetic particle-bsa-biotin. Under action of external magnetic field, superfluous biotin reagent is removed. Degree of reaction between n-hydroxyl succimide ester and magnetic particles is tested by enzyme immunoassay method. It is determined that final obtained solution is high-purified thyroxin labeled by biotin. Advantages of the invention are simple, quick and high efficiency. The invention is also applicable for separating and purifying biomoleculars of protein, polypeptide, oligonucleotide etc. labeled by biotin.

The present invention provides a compound having the structure:whereinX is a therapeutic agent containing at least one amine nitogen and the amine nitrogen on the therapeutic agent covalently bonds directly to carbon α;Z is CH3 or CF3;R1 is —H, —NR2R3, —NH—C(═O)—R4, —NH—C(═O)—OR4, —CH2—C(═O)—NR5R6, —OR7, —CO2R7, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, or heteroaryl,wherein R2, R3, R4, R5, R6 and R7 are each, independently, —H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide;wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; andn is an integer from 0 to 6;or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.

The invention relates to a neck skin care product and a preparation technique thereof. The proportioning for the components of neck skin care product is scientific and reasonable; the neck skin care product comprises active ingredients of Limnanthes Alba seed oil (meadowfoam seed oil), palmitoyl pentapeptide, soliquoid of organosilicone elastomers, etc., and the preparation of the neck skin care product aims at caring the neck skin of pregnant women and lying-in women that is characterized by hydropenia and easy aging caused by escalatory secretion of thyrotropin and corticotrophin; the neck skin care product has prominent anti-oxidation and free radical capturing properties, and is not greasy with strong permeability, obviously reinforcing the synthesis of elastin and collagen protein of the skin, smoothening the wrinkles and promoting skin elasticity; meanwhile, the neck skin care product ensures the skin moist and silken texture and covers the fine wrinkles of the neck; through the synergistic effect on the skin from endothecium to surface, the neck skin care product is capable of promoting the elasticity of the skin, preventing the loss of moisture, supplying moisture and nutrition inside the skin simultaneously, and ensuring the skin of the neck to be healthier and more lustrous.

The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.

The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

The invention provides application of transthyretin in the aspect of serving as a carrier for a protein and / or polypeptide drug to enter an eye through an eye barrier. The transthyretin is a protein consisting of amino acid as shown in SEQ ID NO:1 or a mutation thereof or a modification thereof. The invention further provides application of the transthyretin and / or a fusion protein of the transthyretin and a drug to preparation of a drop and a drop. The drug is the protein and / or polypeptide drug. The transthyretin has good biocompatibility and safety in human bodies, can effectively convey aforeign protein and / or polypeptide into the eye and achieves an effect of treating eye diseases. In an eye dropping manner, when the eye diseases such as DR (Diabetic Retinopathy), AMD (Age-related macular degeneration), ROP (Retinopathy of Prematurity) and the like are treated, the transthyretin can enter a vitreous body and eye ground across a cornea barrier so as to obviously inhibit eyeball retina leakage, obviously reduce the number of retinal new blood vessels and effectively relieve the pathological phenomena of the eye diseases.

The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic-i), e.g., NFD- L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.

The present invention relates to a method of treating or preventing transthyretin amyloidosis, pharmaceutical composition for use in said treatment or prevention, as well as to a diagnostic method and a kit.

Methods are provided for the establishment and maintenance in long term culture of hormone secreting cells. Cells are derived from tumorous or non-tumorous animal or human tissues, including ovary, endometrium, trophoblast, pituitary, thyroid, and pancreas. The cells secrete into the culture medium hormones such as estrogens, progestins, follicle-stimulating hormone, luteinizing hormone, human chorionic gonadotrophin, thyroxin, glucagon, and insulin, depending on the tissue of origin of individual cell cultures. Contact with an appropriate secretogogue causes the cells to respond with increased hormone secretion. For instance, ovarian follicular cells respond to follicle-stimulating hormone with increased estrogen and progesterone secretion. Pancreatic cells respond to elevated glucose with increased insulin secretion. The cells proliferate in in vitro for up to one year or longer, during which time they retain their hormone-secretion profile. The cells may be frozen for storage, and retain their hormone-secretion profile after thawing. The cell cultures are useful for the production of human hormones, for the bio-assay of drugs such as therapeutic gonadotrophin, for the testing of drug efficacy and design, and for toxicity testing of drugs and chemicals. The cells may also be implanted in an individual to replace deficient hormone secretion. For instance, insulin secreting pancreatic cells may be implanted in a diabetic individual as an adjunct or replacement therapy for exogenously administered insulin.

A mufti-organ gene profiling analysis of the results of an administration to a subject of salmon calcitonin or a parathyroid hormone analogue provides biomarkers of calcitonin treatment efficacy and parathyroid hormone or parathyroid hormone analogue treatment efficacy. Among the biomarkers are the expression profiles of the genes for Y-box binding protein, BMPs, FGFs, IGFs, VEGF, &x3B1;-2-HS glycoprotein (AHSG), OSF, nuclear receptors (steroid / thyroid family) and others. The results obtained support the anabolic effect of salmon calcitonin on bone metabolism.

The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

The present invention relates to compounds containing T3 mimetics of phosphonic acid and monoesters, stereoisomers, pharmaceutically acceptable salts, co-crystals thereof, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of prodrugs thereof, and Their preparation and use in the prevention and / or treatment of metabolic diseases such as obesity, nonalcoholic steatohepatitis (NASH), hypercholesterolemia and hyperlipidemia, and related conditions such as atherosclerosis, coronary Cardiac disease, impaired glucose tolerance, metabolic syndrome x, and diabetes uses.

The invention discloses the expressing product of human thyrotropin receptor extracellular domain amino terminus gene and its preparation methods and the application of the product in the enzyme immunoassay technology. The purpose of this invention is to divide TSHR-ecd cDNA into three regions(hTSHR-N terminal, hTSHR-C terminal and hTSHR-M terminal), clone them respectively, especially the hTSHR-N terminal, construct expression vector, express in E.coli, and establish TRAb (including TSAb. TSBAb) ELISA technology taking the protein of this gene engineering fragmentas antigen. The said invention develops novel channel for further research of TSHR antigen determinant and settles foundation for the ultimate transformation into TSAb, TSBAb clinical diagnostic kit.